Beta-O2 Technologies Ltd. Revenue and Competitors

Beta-O2 is developing the ßAir Bio-artificial Pancreas, intended to cure Type 1 diabetes (TID). Patients with TID are unable to produce insulin, a hormone needed to transport sugar into cells, providing the energy needed for daily life. ßAir provides a viable and safe environment for islets of Langerhans (insulin producing beta cells), to thrive and provide the body with insulin on demand. It is able to do so, as Beta-O2 has solved the major challenges of islet transplantation – creating a protective environment where the cells can thrive but where the patient doesn't need to take life-long immunosuppression drugs with unpleasant side effects, and of crucial importance, keeping the cells alive and functioning inside the recipient's body.